Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Monopar Therapeutics (MNPR) over the last 9 years, with Dec 2024 value amounting to $59.3 million.

  • Monopar Therapeutics' Cash from Financing Activities rose 50810.13% to $6.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.6 million, marking a year-over-year increase of 7252.68%. This contributed to the annual value of $59.3 million for FY2024, which is 2824.80% up from last year.
  • Latest data reveals that Monopar Therapeutics reported Cash from Financing Activities of $59.3 million as of FY2024, which was up 2,824.80% from $2.0 million recorded in FY2023.
  • In the past 5 years, Monopar Therapeutics' Cash from Financing Activities registered a high of $59.3 million during FY2024, and its lowest value of $32,873 during FY2022.
  • In the last 3 years, Monopar Therapeutics' Cash from Financing Activities had a median value of $2.0 million in 2023 and averaged $20.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 99.70% in 2022, then skyrocketed by 6,066.85% in 2023.
  • Monopar Therapeutics' Cash from Financing Activities (Yearly) stood at $8.2 million in 2020, then skyrocketed by 32.97% to $10.9 million in 2021, then slumped by 99.70% to $32,873 in 2022, then skyrocketed by 6,066.85% to $2.0 million in 2023, then skyrocketed by 2,824.80% to $59.3 million in 2024.